Pretreatment features of CN-AML patients
| Characteristic . | DFS ≥ 10 y, n = 113 . | DFS < 10 y, n = 433 . | P* . |
|---|---|---|---|
| Age, y | .29 | ||
| Median | 43 | 45 | |
| Range | 18-59 | 18-59 | |
| Male sex, n (%) | 53 (47) | 217 (50) | .60 |
| Race, n (%) | .19 | ||
| White | 94 (84) | 384 (89) | |
| Nonwhite | 18 (16) | 48 (11) | |
| Hemoglobin, g/dL | .15 | ||
| Median | 9.2 | 9.1 | |
| Range | 4.6-14.2 | 4.3-16.0 | |
| Platelet count, ×109/L | .79 | ||
| Median | 54 | 60 | |
| Range | 3-502 | 7-569 | |
| WBC count, ×109/L | .04 | ||
| Median | 14.8 | 20.7 | |
| Range | 0.8-165.1 | 0.5-318.4 | |
| Percentage of blood blasts | .68 | ||
| Median | 48 | 50 | |
| Range | 1-94 | 0-97 | |
| Percentage of bone marrow blasts | .04 | ||
| Median | 63 | 68 | |
| Range | 10-97 | 4-97 | |
| Extramedullary involvement, n (%) | 34 (31) | 132 (31) | 1.00 |
| CNS | 2 (2) | 1 (0) | .11 |
| Hepatomegaly | 5 (5) | 23 (5) | 1.00 |
| Splenomegaly | 2 (2) | 25 (6) | .09 |
| Lymphadenopathy | 13 (12) | 61 (14) | .64 |
| Skin infiltrates | 7 (6) | 36 (8) | .56 |
| Gum hypertrophy | 16 (14) | 56 (13) | .75 |
| Mediastinal mass | 0 (0) | 1 (0) | 1.00 |
| Characteristic . | DFS ≥ 10 y, n = 113 . | DFS < 10 y, n = 433 . | P* . |
|---|---|---|---|
| Age, y | .29 | ||
| Median | 43 | 45 | |
| Range | 18-59 | 18-59 | |
| Male sex, n (%) | 53 (47) | 217 (50) | .60 |
| Race, n (%) | .19 | ||
| White | 94 (84) | 384 (89) | |
| Nonwhite | 18 (16) | 48 (11) | |
| Hemoglobin, g/dL | .15 | ||
| Median | 9.2 | 9.1 | |
| Range | 4.6-14.2 | 4.3-16.0 | |
| Platelet count, ×109/L | .79 | ||
| Median | 54 | 60 | |
| Range | 3-502 | 7-569 | |
| WBC count, ×109/L | .04 | ||
| Median | 14.8 | 20.7 | |
| Range | 0.8-165.1 | 0.5-318.4 | |
| Percentage of blood blasts | .68 | ||
| Median | 48 | 50 | |
| Range | 1-94 | 0-97 | |
| Percentage of bone marrow blasts | .04 | ||
| Median | 63 | 68 | |
| Range | 10-97 | 4-97 | |
| Extramedullary involvement, n (%) | 34 (31) | 132 (31) | 1.00 |
| CNS | 2 (2) | 1 (0) | .11 |
| Hepatomegaly | 5 (5) | 23 (5) | 1.00 |
| Splenomegaly | 2 (2) | 25 (6) | .09 |
| Lymphadenopathy | 13 (12) | 61 (14) | .64 |
| Skin infiltrates | 7 (6) | 36 (8) | .56 |
| Gum hypertrophy | 16 (14) | 56 (13) | .75 |
| Mediastinal mass | 0 (0) | 1 (0) | 1.00 |
Pretreatment features of CN-AML patients aged <60 y with DFS of ≥10 y and of those with DFS <10 y.
P values for categorical variables are from Fisher's exact test. P values for continuous variables are from the Wilcoxon rank sum test.